Powered by

GNW: Actelion is granted marketing authorization by the European Commission for

Mar 7, 2017 - AWP OTS (Original Text Service)

Ledaga (chlormethine gel) for the treatment of MF-CTCL

ALLSCHWIL/BASEL, SWITZERLAND - 07 March 2017- Actelion Ltd (SIX: ATLN) announced today that the European Commission has granted marketing authorization for the use of Ledaga(R) (chlormethine gel) 160 micrograms/g for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).

MF-CTCL is a rare, potentially life-threatening immune system cancer that is chronic and usually progresses slowly. The course of disease i

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox